Although chemotherapy is an effective cancer treatment, it’s shotgun approach also damages healthy cells bringing debilitating side effects such as nausea, liver toxicity and a battered immune system. Now a new way to deliver this life-saving therapy to cancer patients by getting straight to the source of the disease has been developed. The researchers responsible for the breakthrough delivery vehicle liken it to a cluster bomb for cancer because of its ability to deliver the drugs directly into cancer cells before releasing its chemotherapeutic payload.
The nano-sized delivery vehicle developed by Dr. Dan Peer and Prof. Rimona Margalit of Tel Aviv University (TAU) delivers chemotherapy drugs directly into cancer cells while avoiding interaction with healthy cells, increasing the efficiency of treatment while reducing side effects.
"The vehicle is very similar to a cluster bomb," explains Dr. Peer. Inside the nano-vehicle itself are tiny particles of chemotherapy drugs. When the delivery vehicle comes into contact with cancer cells, it releases the chemotherapeutic payload directly into the cell. According to Dr. Peer, the nanomedical device can be used to treat many different types of cancer, including lung, blood, colon, breast, ovarian, pancreatic, and even several types of brain cancers.
"When the nano-vehicle interacts with the receptor on the cancerous cell, the receptor undergoes a structural change and the chemotherapy payload is released directly into the cancer cell, which leads to more focused chemotherapeutic treatment against the diseased cells," says Dr. Peer.
Because the nano-vehicle reacts only to cancer cells, the healthy cells that surround them remain untouched and unaffected by the therapy. The nano-vehicle itself, adds Dr. Peer, is made from organic materials which fully decompose in the body once it has performed its function, making the treatment safer than current therapies.
Drs. Peer and Margalit are working with ORUUS Pharma in California, which has licensed the "cluster bomb" platform from the university to facilitate a quick transition from the lab to clinical trials, which should begin in two years or less, says Dr. Peer.
See the stories that matter in your inbox every morning